NVZMY OTC
Novozymes A/S
1W: -3.7%
1M: -11.6%
3M: -1.6%
YTD: +0.4%
1Y: +1.1%
3Y: +59.9%
5Y: -10.5%
$62.60
+0.44 (+0.71%)
Weekly Expected Move ±3.3%
$58
$61
$63
$65
$67
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$4.2B
+8.5% ▲
5Y CAGR: -21.6%
Gross Profit
$2.2B
+23.9% ▲
5Y CAGR: -22.2%
Operating Income
$883M
+33.9% ▲
5Y CAGR: -24.7%
Net Income
$584M
+90.8% ▲
5Y CAGR: -27.1%
EPS (Diluted)
$1.25
+13.6% ▲
5Y CAGR: -34.1%
EBITDA
$1.4B
-82.8% ▼
5Y CAGR: -22.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $15.0B | $17.6B | $17.9B | $3.8B | $4.2B |
| YoY Growth | +6.7% | +17.4% | +2.0% | -78.6% | +8.5% |
| Cost of Revenue | $6.3B | $8.0B | $8.2B | $2.0B | $1.9B |
| Gross Profit | $8.6B | $9.6B | $9.7B | $1.8B | $2.2B |
| Gross Margin | 57.7% | 54.6% | 54.3% | 47.2% | 53.9% |
| R&D Expenses | $2.0B | $2.0B | $2.0B | $413M | -$416M |
| SG&A Expenses | $2.8B | $3.2B | $3.3B | $766M | $912M |
| Operating Expenses | $4.7B | $5.0B | $5.7B | $1.2B | $1.4B |
| Operating Income | $4.0B | $4.6B | $4.0B | $659M | $883M |
| Operating Margin | 26.8% | 26.4% | 22.2% | 17.2% | 21.2% |
| Interest Expense | $102M | $102M | $23M | $76M | $68M |
| Income Before Tax | $3.9B | $4.6B | $3.9B | $417M | $743M |
| Tax Expense | $779M | $870M | $870M | $111M | $160M |
| Net Income | $3.1B | $3.7B | $3.0B | $306M | $584M |
| Net Margin | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% |
| EPS (Diluted) | $11.23 | $13.19 | $1.46 | $1.10 | $1.25 |
| EBITDA | $5.4B | $6.1B | $5.5B | $8.1B | $1.4B |
| Shares Outstanding | 280M | 279M | 278M | 278M | 467M |